Press Releases

INCLINE VILLAGE, Nev. , May 8, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin , the company's president and chief executive officer, is scheduled to present at the following upcoming conferences: (Logo:

INCLINE VILLAGE, Nev. , May 3, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the first quarter ended March 31, 2012 . (Logo:  http://photos.prnewswire.com/prnh/20110822/SF55808LOGO ) Royalty revenues for the first quarter of 2012 increased five

INCLINE VILLAGE, Nev. , April 27, 2012 /PRNewswire/ --   PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company will release its first quarter financial results for the period ended March 31, 2012 on Thursday, May 3, 2012 after the markets close.

INCLINE VILLAGE, Nev. , April 26, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company has appointed Bruce Tomlinson to the position of vice president and chief financial officer effective as of June 11 , 2012.  Mr.

INCLINE VILLAGE, Nev. , April 12, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the company will hold its annual meeting of stockholders on Tuesday, June 5, 2012 , at 10:00 a.m. Pacific Time for all stockholders of record on April 13, 2012 .

INCLINE VILLAGE, Nev. , March 14, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has paid the March 14, 2012 , regular quarterly dividend payment of $0.15 per share to all stockholders owning shares of PDL as of March 7, 2012 , the record date.

INCLINE VILLAGE, Nev. , March 8, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced royalty revenue guidance for the first quarter ending March 31, 2012 , of approximately $77 million , as compared with actual royalty revenue of $73 million for the first quarter of 2011,

INCLINE VILLAGE, Nev. , March 5, 2012 /PRNewswire/ --  PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the adjusted conversion rate for its: 2.875% Convertible Senior Notes due February 15, 2015 ( February 2015 Notes) is 159.098 shares of common stock per $1,000 principal amount or

INCLINE VILLAGE, Nev. , Feb. 23, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the fourth quarter and full year ended December 31, 2011 . (Logo:   http://photos.prnewswire.com/prnh/20110822/SF55808LOGO ) Total revenues in 2011 were $362 million ,

INCLINE VILLAGE, Nev. , Feb. 21, 2012 /PRNewswire/ --  PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin , the company's president and chief executive officer, is scheduled to present at the following upcoming conferences: (Logo:

INCLINE VILLAGE, Nev. , Feb. 16, 2012 /PRNewswire/ --  PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company will release its fourth quarter and full year financial results for the period ended December 31, 2011 on Thursday, February 23, 2012 after market close.

INCLINE VILLAGE, Nev. , Feb. 7, 2012 /PRNewswire/ --  PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin , the company's president and chief executive officer, is scheduled to present at the 14th Annual BIO CEO & Investor Conference on Monday, February 13, 2012 , at

INCLINE VILLAGE, Nev. , Feb. 2, 2012 /PRNewswire/ --  PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has entered into separate privately negotiated exchange agreements under which it has retired $10,028,000 aggregate principal amount of the Company's 2.875% Convertible Senior

-- Dividend Amount of $0.15 per Share per Quarter --

  INCLINE VILLAGE, Nev. , Jan. 5, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced the settlement and final results of its offer to exchange up to $180,000,000 in aggregate principal amount of outstanding 2.875% Convertible Senior Notes due 2015 (Old Notes), for a like